• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma.

作者信息

Marchesi Francesco, Cirillo Mariangela, Bianchi Antonella, Gately Michela, Olimpieri Odoardo M, Cerchiara Elisabetta, Renzi Daniela, Micera Alessandra, Balzamino Bjorn O, Bonini Stefano, Onetti Muda Andrea, Avvisati Giuseppe

机构信息

Hematology Unit, Campus Bio-Medico University Hospital, Rome, Italy.

Pathology Unit, Campus Bio-Medico University Hospital, Rome, Italy.

出版信息

Hematol Oncol. 2015 Jun;33(2):110-2. doi: 10.1002/hon.2142. Epub 2014 Apr 8.

DOI:10.1002/hon.2142
PMID:24711044
Abstract
摘要

相似文献

1
High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤患者诊断时CD68+/CD163+肿瘤相关巨噬细胞（M2-TAM）的高密度与不良预后因素及不良临床结局显著相关。
Hematol Oncol. 2015 Jun;33(2):110-2. doi: 10.1002/hon.2142. Epub 2014 Apr 8.
2
An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.M2巨噬细胞数量增加预示着接受利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松治疗的弥漫性大B细胞淋巴瘤患者预后不良。
Leuk Lymphoma. 2014 Nov;55(11):2466-76. doi: 10.3109/10428194.2013.879713. Epub 2014 Mar 3.
3
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.伴有或不伴有利妥昔单抗的 CHOP 样化疗治疗预后良好的弥漫性大 B 细胞淋巴瘤的年轻患者：MabThera 国际试验（MInT）组的一项开放性随机研究的 6 年结果。
Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21.
4
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.剂量调整的环磷酰胺、阿霉素、长春新碱和强的松联合利妥昔单抗化疗在预后不良的未经治疗的老年弥漫性大B细胞非霍奇金淋巴瘤患者中的活性和安全性
Cancer. 2011 Aug 1;117(15):3530; author reply 3531. doi: 10.1002/cncr.25948. Epub 2011 Feb 1.
5
Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.弥漫性大B细胞淋巴瘤患者接受R-CHOP治疗时MYC基因座的获得情况与预后
Br J Haematol. 2011 Oct;155(2):274-7. doi: 10.1111/j.1365-2141.2011.08675.x. Epub 2011 Apr 13.
6
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.硼替佐米联合 CHOP-利妥昔单抗方案治疗初治弥漫性大 B 细胞淋巴瘤和套细胞淋巴瘤。
J Clin Oncol. 2011 Feb 20;29(6):690-7. doi: 10.1200/JCO.2010.31.1142. Epub 2010 Dec 28.
7
High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.弥漫性大 B 细胞淋巴瘤非生发中心亚型患者中 Ki-67 高表达提示 R-CHOP 治疗获益有限。
Eur J Haematol. 2012 Jun;88(6):510-7. doi: 10.1111/j.1600-0609.2012.01778.x. Epub 2012 Mar 27.
8
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.在预后不良的未经治疗的弥漫性大 B 细胞非霍奇金淋巴瘤的非常老年患者中，使用利妥昔单抗的剂量调整的输注环磷酰胺、多柔比星、长春新碱和泼尼松化疗的活性和安全性。
Cancer. 2011 Mar 1;117(5):964-73. doi: 10.1002/cncr.25582. Epub 2010 Oct 19.
9
The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.基质细胞标志物 SPARC 可预测接受利妥昔单抗治疗的弥漫性大 B 细胞淋巴瘤患者的生存情况。
Am J Clin Pathol. 2011 Jan;135(1):54-61. doi: 10.1309/AJCPJX4BJV9NLQHY.
10
Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.配对分析比较了接受利妥昔单抗 CHOP 治疗的患者中 T 细胞/组织细胞丰富型大 B 细胞淋巴瘤和弥漫性大 B 细胞淋巴瘤的结局。
Acta Haematol. 2014;131(3):156-61. doi: 10.1159/000353787. Epub 2013 Oct 31.

引用本文的文献

1
Integrating genomic and transcriptome features for characterization and prognostic prediction of angioimmunoblastic T-cell lymphoma.整合基因组和转录组特征用于血管免疫母细胞性T细胞淋巴瘤的特征描述和预后预测。
Ann Hematol. 2025 Sep 4. doi: 10.1007/s00277-025-06589-3.
2
Tumor Microenvironment, Inflammation, and Inflammatory Prognostic Indices in Diffuse Large B-Cell Lymphomas: A Narrative Review.弥漫性大B细胞淋巴瘤中的肿瘤微环境、炎症及炎症性预后指标：一篇叙述性综述
Int J Mol Sci. 2025 Jun 13;26(12):5670. doi: 10.3390/ijms26125670.
3
VSIG4 as a tumor-associated macrophage marker predicting adverse prognosis in diffuse large B-cell lymphoma.
VSIG4作为一种肿瘤相关巨噬细胞标志物可预测弥漫性大B细胞淋巴瘤的不良预后。
Front Immunol. 2025 Jun 5;16:1567035. doi: 10.3389/fimmu.2025.1567035. eCollection 2025.
4
Tumoricidal potential of binary therapy in lymphoma: Role of DC-NK cross-talk and checkpoint inhibitors.二元疗法在淋巴瘤中的杀瘤潜力：树突状细胞-自然杀伤细胞相互作用及检查点抑制剂的作用
Histol Histopathol. 2025 Sep;40(9):1321-1337. doi: 10.14670/HH-18-900. Epub 2025 Mar 7.
5
GNA15 predicts poor outcomes as a novel biomarker related to M2 macrophage infiltration in ovarian cancer.GNA15作为一种与卵巢癌中M2巨噬细胞浸润相关的新型生物标志物，预示着不良预后。
Front Immunol. 2025 Feb 7;16:1512086. doi: 10.3389/fimmu.2025.1512086. eCollection 2025.
6
Targeting fucosyltransferase FUT8 as a prospective therapeutic approach for DLBCL.将岩藻糖基转移酶FUT8作为弥漫性大B细胞淋巴瘤（DLBCL）的一种潜在治疗方法。
Oncogenesis. 2025 Jan 29;14(1):1. doi: 10.1038/s41389-025-00544-7.
7
Critical Role of Extracellular Vesicles in Diffuse Large B-Cell Lymphoma; Pathogenesis, Potential Biomarkers, and Targeted Therapy-A Narrative Review.细胞外囊泡在弥漫性大B细胞淋巴瘤中的关键作用；发病机制、潜在生物标志物及靶向治疗——一篇叙述性综述
Biomedicines. 2024 Dec 12;12(12):2822. doi: 10.3390/biomedicines12122822.
8
Same-Slide Spatial Multi-Omics Integration Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor Microenvironment.同载玻片空间多组学整合揭示肿瘤病毒相关的肿瘤微环境空间重组
bioRxiv. 2024 Dec 22:2024.12.20.629650. doi: 10.1101/2024.12.20.629650.
9
Prognostic model based on M2 macrophage-related signatures for predicting outcomes, enhancing risk stratification, and providing therapeutic insights in diffuse large B-cell lymphoma.基于M2巨噬细胞相关特征构建的预后模型，用于预测弥漫性大B细胞淋巴瘤的预后、加强风险分层并提供治疗见解。
Heliyon. 2024 Dec 9;10(24):e41007. doi: 10.1016/j.heliyon.2024.e41007. eCollection 2024 Dec 30.
10
How lactate affects immune strategies in lymphoma.乳酸如何影响淋巴瘤中的免疫策略。
Front Mol Biosci. 2024 Oct 11;11:1480884. doi: 10.3389/fmolb.2024.1480884. eCollection 2024.